Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV. Data ...
Zacks Investment Research on MSN
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...
On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...
Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...
Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or PAH, has met its primary endpoint. Topline results from the study, called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results